Colossal Biosciences achieves world-first in avian genetics, raising $120M to accelerate dodo de-extinction project. CEO Ben ...

Colossal Biosciences says it’s one step closer to bringing back the dodo. In April, the Dallas company said it had revived ...

On September 12, TD Cowen analyst Brendan Smith reaffirmed a Buy rating on Twist Bioscience Corp. (NASDAQ:TWST) with a $36 price target. His note followed the company’s September 9 presentation at the ...

Twist Bioscience has seen significant share price growth in the past year, driven by innovative DNA synthesis technology and strong revenue growth. Despite challenges in the life sciences industry, ...

Scientists at Colossal Biosciences in Dallas have developed a primordial germ cell for pigeons, advancing efforts to bring the extinct dodo back to life.

Twist Bioscience Corp. and its CEO must defend against allegations that they at least recklessly misled investors with statements about synthetic DNA quality and automated manufacturing.

Nanosecond PFA 360° Cardiac Catheter for AF ablation to be highlighted in presentations and in a live case transmission “We are gaining significant momentum generating clinical and preclinical ...

The parking lot that once held the New Haven Veterans Memorial Coliseum will soon become a bioscience technology hub. The former sports and entertainment arena opened in 1972, closed in 2002 and was ...

The trial will evaluate the effectiveness of the nsPFA cardiac surgical system during concurrent surgical procedures.

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon ...

MIAMI--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, today announced that its nsPFA ...